Recent Publications

Displaying 50 most recent publications. For the full list please visit UCL Discovery

1. Stohr W,Walker AS,Munderi P,Tugume S,Gilks CF,Darbyshire JH,Hakim J,on BOTDARTT (2008) Estimating glomerular filtration rate in HIV-infected adults in Africa: comparison of Cockcroft-Gault and MDRD formulae Antiviral Therapy, 13(6), 761 - 770.
2. Campbell N,Murray E,Darbyshire J,Emery J,Farmer A,Griffiths F,Guthrie B,Lester H,Wilson P,Kinmonth AL (2007) Designing and evaluating complex interventions to improve health care BMJ (Clinical Research Ed.), 334(7591), 455 - 459. 10.1136/bmj.39108.379965.BE.
3. Asboe D,Williams IG,Goodall RL,Darbyshire JH,Hooker MH,Babiker AG (2007) A virological benefit from an induction/maintenance strategy: the Forte trial. Antiviral Therapy, 12(1), 47 - 54.
4. Vickers MR,MacLennan AH,Lawton B,Ford D,Martin J,Meredith SK,DeStavola BL,Rose S,Dowell A,Wilkes HC,Darbyshire JH,Meade TW (2007) Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ (Clinical Research Ed.), 335(7613), 239. 10.1136/bmj.39266.425069.AD.
5. Kaleebu P,Pillay D,Walker AS,Robertson V,Gale C,Enzama R,Yirrell D,Lyagoba F,Kityo C,Munderi P,Reid A,Gibb DM,Bray D,Burke A,Ait-Khaled M,Darbyshire JH,Muygenyi P,Hakim J,Grosskurth H,Gilks C,DART VGATT (2006) Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa AIDS, 20(10), 1391 - 1399.
6. Yeni P,Cooper DA,Aboulker JP,Babiker AG,Carey D,Darbyshire JH,Floridia M,Girard PM,Goodall RL,Hooker MH,Mijch A,Meiffredy V,Salzberger B (2006) Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both INITIO: open-label randomised trial. The Lancet, 368(9532), 287 - 298. 10.1016/S0140-6736(06)69074-0.
7. El-Sadr WM,Lundgren JD,Neaton JD,Gordin F,Abrams D,Arduino RC,Babiker A,Burman W,Clumeck N,Cohen CJ,Cohn D,Cooper D,Darbyshire J,Emery S,Fätkenheuer G,Gazzard B,Grund B,Hoy J,Klingman K,Losso M,Markowitz N,Neuhaus J,Phillips A,Rappoport C (2006) CD4+ count-guided interruption of antiretroviral treatment New England Journal of Medicine, 355(22), 2283 - 2296. 10.1056/NEJMoa062360.
8. Ssali F,Stohr W,Munderi P,Reid A,Walker AS,Gibb DM,Mugyenyi P,Kityo C,Grosskurth H,Hakim J,Byakwaga H,Katabira E,Darbyshire JH,Gilks CFDARTTT (2006) Prevalence, incidence and predictors or severe anaemia of zidovudine-containing regimens in African adults with HIV infection within the DART Trial Antiviral Therapy, 11(6), 741 - 749.
9. Newton R,Carpenter L,Casabonne D,Beral V,Babiker A,Darbyshire J,Weller I,Weiss R,Kwan A,Bourboulia D,Munoz F,Lagos D,Boshoff C (2006) A prospective study of Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus in adults with human immunodeficiency virus-1 BRITISH JOURNAL OF CANCER, 94(10), 1504 - 1509. 10.1038/sj.bjc.6603100.
10. Grant AM,Altman DG,Babiker AG,Campbell MK,Clemens F,Darbyshire JH,Elbourne DR,McLeer SK,Parmar MKB,Pocock SJ,Spiegelhalter DJ,Sydes MR,Walker AE,Wallace SA (2005) A proposed charter for clinical trial data monitoring committees: helping them to do their job well. The Lancet, 365(9460), 711 - 722. 10.1016/S0140-6736(05)17965-3.
11. Babiker AG,Breckenridge A,Darbyshire JH,Dunn DT,Fakoya A,Fisher M,Leigh Brown A,Loveday C,McCormack S,Pillay D,Poppa A,Rinehart A,Verbiest W,Williams I,Era SC (2005) A randomised controlled trial of the clinical utility of genotypic resistance testing in patients with limited prior exposure to antiretroviral drugs HIV Clinical Trials, 6(4), 183 - 186.
12. Maskell NA,Davies CW,Nunn AJ,Hedley EL,Gleeson FV,Miller R,Gabe R,Rees GL,Peto TE,Woodhead MA,Lane DJ,Darbyshire JH,Davies RJ (2005) UK controlled trial of intrapleural streptokinase for pleural infection. First Multicentre Intrapleural Sepsis Trial (MIST1 Group) New England Journal of Medicine, 352(9), 865 - 874. 10.1056/NEJMoa042473.
13. Aboulker JP,Babiker A,Chaix ML,Compagnucci A,Darbyshire J,Debre M,Faye A,Giaquinto C,Gibb DM,Harper L,Saidi Y,Walker AS (2004) Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome Aids, 18(2), 237 - 245.
14. Dunn DT,Gibb DM,Babiker AG,Green H,Darbyshire JH,Weller IV (2004) HIV drug resistance testing: is the evidence really there? Antiviral Therapy, 9(5), 641 - 648.
15. Phillips AN,Pezzotti P (2003) Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era AIDS, 18(1), 51 - 58. 10.1097/00002030-200401020-00006.
16. Dunn DT,Gibb DM,Babiker AG,Darbyshire JH,Green H (2003) A methodological critique of RCTs of HIV drug resistance testing. Controlled Clinical Trials, Design, Methods and Analysis (poster) Official Journal of the Society for Clinical Trials, 24(3S (P1).
17. Gibb DM,Giaquinto C,Walker AS,Harper LM,Compagnucci A,Saidi Y,Moulinier C,Aboulker JP,Babiker AG,Debre M,Darbyshire JH (2003) , on behalf of the PENTA 5 Steering Committee. Three year follow-up of the PENTA 5 Trial [Abstract G1-12 (poster)].
18. CASCADE Collaboration (2003) Determinants of survival following HIV-1 seroconversion after the introduction of HAART The Lancet, 362(9392), 1267 - 1274. 10.1016/S0140-6736(03)14570-9.
19. CASCADE Collaboration (2003) Short-term CD4 cell response after highly active antiretroviral therapy initiated at different times from seroconversion in 1,500 seroconverters JAIDS: Journal of Acquired Immune Deficiency Syndromes, 32(3), 303 - 310.
20. Mwinga A,Nunn A,Ngwira B,Chintu C,Warndorff D,Fine P,Darbyshire J,Zumla A (2002) Randomized placebo-controlled clinical trial of Mycobacterium vaccae (SRL172) immunotherapy as an adjunct to standard antituberculosis treatment in HIV-infected adults with pulmonary tuberculosis. The Lancet, 360(9339), 1050 - 1055. 10.1016/S0140-6736(02)11141-X.
21. Paediatric European Network for the Treatment of AIDS (PENTA), (2002) Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial The Lancet, 359(9308), 733 - 740. 10.1016/S0140-6736(02)07874-1.
22. Rabkin M,El-Sadr W,Katzenstein DA,Mukherjee J,Masur H,Mugyenyi P,Munderi P,Darbyshire J (2002) Antiretroviral treatment in resource-poor settings: clinical research priorities The Lancet, 360(9344), 1503 - 1505.
23. CASCADE Collaboration (2002) Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks International Journal of Epidemiology, 31(5), 951 - 958.
24. Aboulker JP,Babiker A,Darbyshire JH,Debre M,Giaquinto C,Gibb DM,Harper L,Newberry A,Saidi Y,Levy J,Della N,Forbes J,Vaudry W,Mechinaud F,Nicolas J,Wahn V,Dammann C,Notheis G,Hinkelmann B,Butler K,De Manzini A,Mazza A,Duse M,Loy A,Plebani A,Castelli-Gattinara G,Cellini M,Palomba E,Caselli D,Guarino A,Osimani P,Scherpbier H,Delgado A,Gomez ID,Lecuona JE,Pena MJM,Baselga C,Leal JAL,Amador JTR,Canosa C,Sierra AM,Calavia LC,Rodrigo C,Guasch CF,Bohlin A,Nadal D,Mok J,Lyall H,Novelli V,Sharland M,Sloper K (2001) Five year follow up of vertically HIV infected children in a randomised double blind controlled trial of immediate versus deferred zidovudine: the PENTA 1 trial Archives of Disease in Childhood, 84(3), 230 - 236.
25. Babiker AG,Peto T,Porter K,Walker AS,Darbyshire JH (2001) Age as a determinant of survival in HIV infection Journal of Clinical Epidemiology, 54(S1), S16 - S21.
26. Porter K,Babiker A,Walker S,Darbyshire J,Gill N,Beral V,Coutinho R,Darbyshire J,Gill N,Lee C,Meyer L,Rezza G,Porter K,Babiker A,Walker S,Darbyshire J,Tyrer F,Dabis F,Marimoutou C,Meyer L,Boufassa F,Hamouda O,Brunn M,Pezzotti P,Rezza G,Lorenzo JI,Touloumi G,Hatzakis A,Karafoulidou A,Katsarou O,Brettle R,Del Amo J,del Romero J,Prins M,Coutinho RA,van Benthem B,Coutinho RA,Kirk O,Pedersen C,AGuado IH,Perez-Hoyos S,Eskild A,Bruun JN,Sannes M,Sabin C,Lee C,Johnson AM,Phillips AN,Babiker A,Darbyshire JH,Gill N,Porter K,Egger M,Francioli P,Rickenbach M,Cooper D,Kaldor J,Cooper D,Kaldor J,Vizzard J,Tusell JM,Ruiz I,Cayla JA,de Olalla PG,Day NE,De Angelis D,CASCADE Collaboration (2000) Effect of ignoring the time of HIV seroconversion in estimating changes in survival over calendar time in observational studies: results from CASCADE AIDS, 14(13), 1899 - 1906.
27. Toloumi G,Pocock SJ,Babiker AG,Darbyshire JH (1999) Estimation and comparison of rates of change in longitudinal studies with informative drop-outs Statistics in Medicine, 18(10), 1215 - 1233.
28. Porter K,Johnson AM,Phillips AN,Darbyshire JH (1999) The practical significance of potential biases in estimates of the AIDS incubation period distribution in the UK register of HIV seroconverters AIDS, 13(14), 1943 - 1951.
29. Parazzini F,Ricci E,DiCintio E,Chiaffarino F,Pardi G,Bortolus R,DOro LC,Biraghi P,Bucceri A,Ravizza M,Grossi E,Muggiasca ML,Tibaldi C,Prati A,Iasci A,Aronica E,Ceccarelli E,Frigerio L,Borlone P,Stagnizza M,Agnoletto V,Tognoni G,Lazzrin A,Massobrio M,Garzetti GG,Ciavattini A,Mosca S,Greco P,Vimercati A,Guerra B,Bianchi S,Bovicelli L,Prati E,Innocenti TA,Fiscella A,Rossi G,Rancilio L,Ferraris G,Vignali M,Semprini AE,Castagna C,DellaTorre M,Martinelli P,Sansone M,diLenardo L,Russolo A,Rubino E,LoBue G,Maccabruni A,Arlandi L,Citernesi A,Villa P,Mancuso S,Pachi A,Scaravelli G,Benedetto C,Ziarati N,Gabiano C,Alberico S,Franchi M,Zanconato G,Fedele L,Newell ML,Bailey A,Peckham C,Darbyshire J,Sanchez E,Leyes M,Ciria LM,Coll O,Fortuny C,Bogunya JM,Paya A,Mur A,Casellas M,Lain J,Anzen B,Lindgren S,Rudin C,Irion O,Bewley S,Kennedy J,Mandelbrot L,Bazin B,Aboulker JP,CrennHebert C,Tudal CF,Bech A,Lobut R,Chemla JP,Milliez J,Courpotin C,Firtion G,Benifla JL,Ottenwalter A,Vilmer E,Hocke C,Douard D,Berrebi A,Tricoire J,Pauly I,LeLorier B,Bongain A,Monpoux F,Cravello L,Perrimond H,Blanche S (1999) Elective caesarean-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial The Lancet, 353, 1035 - 1039.
30. White IR,Babiker AG,Walker AS,Darbyshire JH (1999) Randomization-based methods for correcting for treatment changes: examples from the Concorde trial Statistics in Medicine, 18(19), 2617 - 2634.
31. McCormack S,Tilzey A,Carmichael A,Gotch F,Kepple J,Newberry A,Jones G,Beddows S,Cheinsong R,Rees A,Banatvala J,Bruck C,Darbyshire J,Tyrrel D,Van Hoecke C,Weber J (1999) Immunogenecity and safety in HIV negative healthy volunteers of a recombinant gp120 w61D derived from dual tropic R5X4 HIV-1 ACH320 and adjuvanted with 3D-MPL/QS21 with or without an oil and water emulsion, or with alum Vaccine.
32. Hooker MH,Arlett PR,Lee GH,Cave AH,Darbyshire JH,Breckenridge AM,Rawlins M (1998) HIV adverse drug reaction (ADR) reporting scheme(No. 12).
33. Tedder RS,Kaye S,Loveday C,Weller IV,Jeffries D,Norman J,Weber J,Bourelly M,Foxall R,Babiker A,Darbyshire JH (1998) Comparison of culture- and non-culture-based methods for quantification of viral load and resistance to antiretroviral drugs in patients given Zidovudine monotherapy Journal of Clinical Microbiology, 36, No(April), 1056 - 1063.
34. Arlett PR,Lee EH,Cave AC,Hooker M,Darbyshire JH,Breckenridge AM,Rawlins M (1998) UK HIV Adverse Drug Reactions Reporting Scheme AIDS, 12(4), 156.
35. Tedder RS,Kaye S,Loveday C,Weller IVD,Jeffries D,Norman J,Weber J,Bourelly M,Foxall R,Babiker A,Darbyshire JH (1998) A comparison of culture and non-culture methods for the quantification of viral load and anti-retroviral drug resistance in patients on zidovudine monotherapy Journal of Clinical Microbiology, 36(4), 1056 - 1063.
36. Evans B,Darbyshire J,Cartledge J (1998) Should preventive antiretoviral treatment be offered following sexual exposure to HIV? Sexually Transmitted Infections, 74, 146 - 148.
37. Kinghorn GR,Evans B,Nunn A,Darbyshire J,Adler MW,Carne CA (1998) Post-exposure prophylaxis (PEP) after non-occupational risk of HIV infection Sexually Transmitted Infections, 74(4).
38. Yeni P,Aboulker JP,Halley A,Nunn A,Brun-Vezinet F,Gazzard B,Darbyshire JH,Delta CC (1998) A randomized study comparing treatment with AZT plus 3TC, ddI or ddC in 254 nucleoside experienced HIV infected patients(No. 66).
39. Ormerod LP,Charlett A,Gilham C,Darbyshire J,Watson JM (1998) Geographic distribution of tuberculosis notifications in national surveys of England and Wales in 1988 and 1993 : report of the Public Health Laboratory Service/British Thoracic Society/Department of Health Collaborative Group Thorax, 53, 176 - 181.
40. Newell M,Parazzini F,Mandelbrot L,Peckham C,Semprini A,Bazin B,Darbyshire J,Sanchez E,Pardi G (1998) A randomised trial of mode of delivery in women infected with the human immunodeficiency virus British Journal of Obstetrics and Gynaecology, 105, 281 - 285.
41. Babiker A,Hughes M,Darbyshire JH (1998) The role of HIV-1 RNA as a surrogate marker for clinical outcome in clinical trials evaluating new anti-HIV therapies Antiviral News, 6(1), 10 - 11.
42. Babiker A,Darbyshire JH,Peto TEA,Walker AS (1998) Issues in the design and analysis therapeutic trials in HIV infection Journal of the Royal Statistical Society: Series A (Statistics in Society), 161(2), 239 - 249. 10.1111/1467-985X.00102.
43. Walker AS,Peto TEA,Babiker AG,Darbyshire JH,Concorde Co-ordinating Comm (1998) Markers of HIV infection in the Concorde Trial QJM-INT J MED, 91(6), 423 - 438.
44. Arlett PR,Lee EH,Hooker MH,Darbyshire JH,Breckenridge AM (1997) Reporting adverse drug reactions in HIV infection Genitourinary Medicine, 73, 335 - 335.
45. Aaby P,Babiker AG,Darbyshire JH (1997) Ethics of HIV trials The Lancet, 350, 1546 - 1547.
46. Peto TEA,Babiker AG,Darbyshire JH (1997) AIDS Clinical Trials. Editors : Finkelstein, D.M., Schoenfeld, D.A., John Wiley & Sons NY (1995).
47. White IR,Walker AS,Babiker AG,Darbyshire JH (1997) Impact of treatment changes on the interpretation of the Concorde trial AIDS, 11, 999 - 1006.
48. Babiker AG,Hughes M,Darbyshire JH (1997) The role of HIV-1 RNA as a surrogate marker for clinical outcome in clinical trials evaluating new anti-HIV therapies Antiviral News, 6(1).
49. Kumar D,Watson JM,Charlett A,Nicholas S,Darbyshire JH (1997) Tuberculosis in England and Wales in 1993 : results of a national survey Thorax, 52(12), 1060 - 1067.
50. Lehner T,Biberfeld P,Boucher C,Darbyshire J,Fenyo EM,Heeney JL,Jager JC,Lundgren JD,Newell ML,Rosch P,Rossi P,Virelizier JL (1997) European contribution to the science, prevention and management of HIV infection Vaccine, 15(5), 465 - 468.